Zelsuvmi for Molluscum Contagiosum: Clinical Evidence, Mechanisms, and Therapeutic Significance

Molluscum contagiosum (MC) is a highly contagious viral dermatologic disease that predominantly affects children, immunocompromised individuals, and sexually active young adults. This skin condition, characterized by raised, flesh-colored papules with central umbilication, is caused by the MC virus (MCV), a member of the poxviridae family. While typically self-limiting, MC can lead to cosmetic concerns, discomfort, and psychosocial impacts. Traditional treatments, such as cryotherapy and curettage, are often painful and may not align with patient-centered care, highlighting the need for better therapeutic options. The recent FDA approval of Zelsuvmi, a topical gel containing 10.3% berdazimer, marks a significant milestone in MC management. Berdazimer, a nitric oxide-releasing agent, inhibits viral replication and exhibits immunomodulatory effects, offering dual-action efficacy in treating MC. Clinical trials, including the pivotal B-SIMPLE4 trial, demonstrated that berdazimer significantly reduces lesion counts, with a favorable safety profile and minimal systemic absorption. In trials, Zelsuvmi showed superior clearance rates compared to vehicle treatments, with notable efficacy even in patients with atopic dermatitis. Common side effects were mild and included localized skin reactions, such as erythema and application site pain. The introduction of Zelsuvmi provides healthcare professionals with a potent, well-tolerated option for managing MC. This advancement addresses a critical gap in MC care, offering improved outcomes and enhanced quality of life for patients.